Increased drug delivery to the brain by P‐glycoprotein inhibition

Although the antidiarrheal loperamide is a potent opiate, it does not produce opioid central nervous system effects at usual doses in patients. On the basis of in vitro studies demonstrating that loperamide is a substrate for the adenosine triphosphate–dependent efflux membrane transporter P‐glycoprotein, we postulated that inhibition of P‐glycoprotein with quinidine would increase entry of loperamide into the central nervous system with resultant respiratory depression.

[1]  R. Kim,et al.  P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. , 1999, Cancer research.

[2]  J. Sheller,et al.  Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. , 1999, The Journal of pharmacology and experimental therapeutics.

[3]  G R Wilkinson,et al.  Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.

[4]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[5]  T. MacDonald,et al.  Treating diarrhoea. Children deserve special attention. , 1997, BMJ.

[6]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[7]  M. Eichelbaum,et al.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. , 1995, British journal of clinical pharmacology.

[8]  V. Nitsche,et al.  Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules). , 1995, International journal of clinical pharmacology and therapeutics.

[9]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[10]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[11]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.

[12]  R. Woosley,et al.  Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.

[13]  D. Breimer,et al.  Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans , 1991, Clinical pharmacology and therapeutics.

[14]  T. Bhutta,et al.  Loperamide poisoning in children , 1990, The Lancet.

[15]  A. Pesce,et al.  CONCOMITANT ADMINISTRATION OF CYCLOSPORIN AND KETOCONAZOLE IN RENAL TRANSPLANT RECIPIENTS , 1989, The Lancet.

[16]  J. Dover,et al.  INTERACTION BETWEEN CYCLOSPORIN AND RIFAMPICIN , 1984, The Lancet.

[17]  Read Dj,et al.  A clinical method for assessing the ventilatory response to carbon dioxide. , 1967 .

[18]  K. Thummel,et al.  In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.

[19]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[20]  J. Endicott,et al.  The biochemistry of P-glycoprotein-mediated multidrug resistance. , 1989, Annual review of biochemistry.

[21]  D. Laurence,et al.  Clinical Pharmacology & Therapeutics , 1980, Palgrave Macmillan UK.

[22]  D. Read,et al.  A clinical method for assessing the ventilatory response to carbon dioxide. , 1967, Australasian annals of medicine.